Allergan
From WikiClimate
Company Details
- Company name: Allergan Inc.
- Country: USA
- Sub Sector: Pharmaceuticals
- Industry Group: Pharmaceuticals, Biotechnology and Life Sciences
- Parent Sector: Health Care
Allergan Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices. Allergan offers a number of leading products including: BOTOX® (Botulinum Toxin Type A), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (Botulinum Toxin Type A), the JUVÉDERM™ family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System.
Founded in 1950, with headquarters in Irvine, California, Allergan employs more than 8,500 people worldwide and operates world-class research and development facilities and state-of-the-art manufacturing plants. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities, with a presence in more than 100 countries.
Carbon Disclosure
The following data is © Carbon Disclosure Project and was provided by Allergan Inc. in response to the Carbon Disclosure Project Greenhouse Gas Emissions questionnaires.
Regulatory risks
Allergan is operating under a GHG permit at its Westport, Ireland location as required and administered by the Irish EPA. The permit was received in 2006. The permit has placed maximum GHG emissions limits on Allergan’s Westport, Ireland facility. The facility has capacity to expand in spite of this restriction. Opportunities have been and are being developed to reduce GHG emissions as well as opportunities for clean development mechanisms or joint implementation programs. Allergan is participating in the European Union Emissions Trading Scheme (EU ETS) in Ireland. Allergan Westport in 2007 reduced direct GHG emissions through projects undertaken during the year and had an excess of GHG emissions credits. These will be sold back to the system. In 2008, the next five year increment of the program begins and a new allocation will be developed. Emission credits are currently selling for one Euro per tonne of CO2e emissions.
In the USA, Allergan has joined the Climate Action Registry in California. Registration of GHG emissions related to Allergan California locations was completed in 2007. Third party verification is required and will be completed in 2008. Potential GHG permit planning regarding California business entities by the California Air Resources Board has begun. Program specifics and permitting requirements are expected in 2008. Allergan is ahead of this process by already collecting data, by implementing energy conservation projects and programs, and by participating in the Climate Action Registry. It is expected that the Climate Action Registry inventory and actions will mirror Allergan’s future GHG permitting requirements.
Other than the Allergan operations mentioned above, Allergan facilities are not being directly impacted by permitting or potential permitting or GHG emissions controls for the moment. However, Allergan’s energy management policy and programs are being evenly applied worldwide.
Allergan continuously monitors emerging proposals, regulations, and directives associated with climate change in order to anticipate and address impact to the business.
Physical risks
Allergan operations are impacted by weather events at each of its operating locations. However, the impacts due to severe weather, changes in weather patterns, rising temperatures, sea level rise and other related phenomena are not expected to have a significant impact directly on Allergan operations. Allergan has established comprehensive emergency response programs at each of our sites to address issues resulting from severe weather.
Allergan uses a number of suppliers and third party manufacturers who may be exposed to physical risks from climate change. These risks are reviewed as a part of the business interruption reviews of these external companies.
General risks
The commercial opportunities are reduced costs to produce goods and improved public perception of Allergan as a concerned environmental company. The commercial risks include limitations on Irish manufacturing facility production output due to GHG permit constraints in the future.
The production of Allergan products as mentioned above does impact GHG emissions through energy efficient operations, and Allergan has a comprehensive energy management plan and objectives in place to make a positive impact in reducing these emissions. The transportation of Allergan product and the sales associates’ use of fuel in vehicles to service customers are areas that Allergan is developing opportunities to reduce GHG emissions. Allergan is studying the use of higher fuel efficient vehicles in various parts of the world. A survey indicated that vehicle fuel efficiency in Australia, the USA and Canada could be improved to match the EU fuel efficiency. The implementation of these opportunities will follow their development and feasibility determination. Allergan will work with product distributors to ensure that fuel efficiency is being effectively managed.
General and regulatory risks management
Allergan believes that climate change is occurring. Allergan also realizes that being energy efficient as well as production efficient makes the company more competitive along with protecting the environment by reducing GHG emissions. The commercial risk for Allergan and all businesses is to ignore and not plan for energy efficiency. Allergan is not missing this opportunity. Allergan has an extensive Energy Management Policy and Plan that have been in existence for many years. The basic outline of the current five year plan follows. The Plan is divided into several sections:
1. Existing Facilities Energy Efficiency Opportunities 2. New Construction Energy Efficiency Opportunities 3. Onsite Power Generation Opportunities 4. Energy Procurement and Planning 5. Energy Conservation Communications
The Allergan Energy Management Policy and performance against targets can be viewed at here
In the USA, Allergan has joined the Climate Action Registry in California. Registration of GHG emissions related to Allergan California locations has been completed for 2006 and 2007. Third party verification will be completed in 2008. Potential GHG permit planning regarding California business entities by the California Air Resources Board has begun. Program specifics and permitting requirements are expected to be finalized in 2008. Allergan is ahead of this process by already collecting data, by implementing energy conservation projects and programs, and by participating in the Climate Action Registry. It is expected that the Climate Action Registry inventory and actions will mirror Allergan’s future GHG permitting requirements.
Other than the Allergan operations mentioned above, Allergan facilities are not being directly impacted by permitting or potential permitting or GHG emissions controls for the moment. However, Allergan’s energy management policy and programs are being evenly applied worldwide.
Allergan’s products do not have an impact relating to GHG emissions directly. The production of Allergan products as mentioned above does impact GHG emissions through energy efficient operations, and Allergan has a comprehensive energy management plan and objectives in place to make a positive impact in reducing these emissions. The transportation of Allergan product and the sales associates’ use of fuel in vehicles to service customers are areas that Allergan is developing opportunities to reduce GHG emissions. Allergan has implemented the use of higher fuel efficient vehicles in various parts of the world. Allergan will work with product distributors to ensure that fuel efficiency is being effectively managed.
Current and/or future financial effects of risks
Allergan analyzes the regulatory, business and physical impacts that might impact Allergan’s business. Costs are for such activities as energy consumption, GHG emissions, and transportation of raw materials and finished products.
Opportunities presented by current or anticipated regulatory requirements on climate change
If Allergan implements its energy strategy as planned, it will put Allergan ahead of competitors and allow the company to become more competitive. Allergan has participated in voluntary programs such as the California Climate Action Registry in anticipation of expected regulatory actions by the California Air Resources Board. This will allow Allergan to be more competitive with other companies that have not begun the inventory and strategy process but will be driven by reacting to compliance requirements.
Opportunities presented by current or anticipated physical changes resulting from climate change
As a healthcare company we will evaluate opportunities to address healthcare issues that arise as a result of climate change.
General opportunities presented by climate change
The commercial opportunities are reduced costs to produce goods and improved public perception of Allergan as a concerned environmental company.
The production of Allergan products as mentioned above does impact GHG emissions through energy efficient operations, and Allergan has a comprehensive energy management plan and objectives in place to make a positive impact in reducing these emissions. The transportation of Allergan product and the sales associates’ use of fuel in vehicles to service customers are areas that Allergan is developing opportunities to reduce GHG emissions. Allergan is studying the use of higher fuel efficient vehicles in various parts of the world. A survey indicated that vehicle fuel efficiency in Australia, the USA and Canada could be improved to match the EU fuel efficiency. The implementation of these opportunities will follow their development and feasibility determination. Allergan will work with product distributors to ensure that fuel efficiency is being effectively managed.
Planned investment in products and services designed to minimise/adapt to effects of climate change
Climate change has led to investment or planned investment in order to maximise climate change opportunities.
Factors which minimize the impact of our products on climate change are considered throughout the product design cycle. Substitution to less hazardous material, reduction in the use of material, and increasing product potency are examples of our investments that reduce impact on climate change.
Future financial effects of opportunities presented by climate change
The initiatives implemented will result in a reduction in costs and provide Allergan a competitive advantage. There is also direct saving from reduction of energy and fuel used by our operations.
Greenhouse Gas Emissions
- Greenhouse Gas emissions methodology used: GHG Protocol. GHG emissions are calculated using emissions factor provided by WRI GHG protocol, and for California, USA locations factors provided by the California Climate action Registry. Emissions of less than 5% were considered de minimis and not always included.
- Accounting year: 01/01/2007 to 31/12/2007
- Total global Scope 1 activity in Metric Tonnes CO2-e emitted: 41,220
- Total global Scope 2 activity in metric tonnes CO2-e emitted: 77, 533
